
    
      The study consists in a 6-month treatment period followed by an observational period of 3 to
      6 months with a month 9 visit and a phone/contact visit at month 12.

      All participants who complete the 6-month treatment period are re-randomized to either the
      idrabiotaparinux/idraparinux bioequipotency sub-study or the avidin neutralizing effect
      sub-study.
    
  